Doğrulama için verilen süre doldu. Lütfen yenileyin.

Şifremi Unuttum

Merck, ABD’deki Pegile İnterferon Alfa-2b Üretimine Son Vermeye Karar Verdi


PEGINTRON (peginterferon alfa-2b) Vials


Status: Discontinuation

» Therapeutic Categories: Antiviral

Merck Sharp & Dohme Corp. (New 09/24/2015)

Presentation

Posting Date

Related Information

PEGINTRON (peginterferon alfa-2b) injection, 50 mcg per 0.5 mL (NDC 00085-4353-01) 09/24/2015 For business reasons, Merck has decided to voluntarily discontinue the manufacture of PEGINTRON vials, Injection, for subcutaneous use, for distribution in the United States, effective date of February 1, 2016.
PEGINTRON (peginterferon alfa-2b) injection, 80 mcg per 0.5 mL (NDC 00085-4354-01) 09/24/2015 For business reasons, Merck has decided to voluntarily discontinue the manufacture of PEGINTRON vials, Injection, for subcutaneous use, for distribution in the United States, effective date of February 1, 2016.
PEGINTRON (peginterferon alfa-2b) injection, 120 mcg per 0.5 mL (NDC 00085-4355-01) 09/24/2015 For business reasons, Merck has decided to voluntarily discontinue the manufacture of PEGINTRON vials, Injection, for subcutaneous use, for distribution in the United States, effective date of February 1, 2016.
PEGINTRON (peginterferon alfa-2b) injection, 150 mcg per 0.5 mL (NDC 00085-4356-01) 09/24/2015 For business reasons, Merck has decided to voluntarily discontinue the manufacture of PEGINTRON vials, Injection, for subcutaneous use, for distribution in the United States, effective date of February 1, 2016.